Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo

[1]  Daniel E Forman,et al.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[2]  John Fuller,et al.  Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials , 2019, The Lancet.

[3]  R. Califf,et al.  Medication Discontinuation in the IMPROVE-IT Trial , 2019, Circulation. Cardiovascular quality and outcomes.

[4]  F. Blanco-Vaca,et al.  Phytosterols in cancer: From molecular mechanisms to preventive and therapeutic potentials. , 2019, Current medicinal chemistry.

[5]  Odyssey Outcomes Investigators.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018 .

[6]  C. Torp-Pedersen,et al.  Incidence of new onset cancer in patients with a myocardial infarction – a nationwide cohort study , 2018, BMC Cardiovascular Disorders.

[7]  R. Giugliano,et al.  Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis , 2018, JAMA cardiology.

[8]  A. Keech,et al.  Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial , 2017, The Lancet.

[9]  R. Collins,et al.  Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial , 2017, The Lancet.

[10]  R. Giugliano,et al.  Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol: A Prespecified Analysis of the IMPROVE-IT Trial , 2017, JAMA cardiology.

[11]  R. Giugliano,et al.  Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. , 2017, Journal of the American College of Cardiology.

[12]  Improve-It Investigators.  Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[13]  R. Califf,et al.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[14]  M. Pfeffer.  Cancer in cardiovascular drug trials and vice versa: a personal perspective. , 2013, European heart journal.

[15]  J. Staessen,et al.  Cardiovascular drugs and cancer: of competing risk, smallpox, Bernoulli, and d'Alembert. , 2013, European heart journal.

[16]  John Simes,et al.  Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy , 2012, PloS one.

[17]  M. Landray,et al.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[18]  R. Califf,et al.  Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. , 2008, American heart journal.

[19]  J. Chambers,et al.  Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. , 2008, The New England journal of medicine.

[20]  M. Landray,et al.  Analyses of cancer data from three ezetimibe trials. , 2008, The New England journal of medicine.

[21]  Allen J. Taylor,et al.  Preliminary Observations From Preliminary Trial Results: Have We Finally Had Enough? , 2008, Circulation. Cardiovascular quality and outcomes.

[22]  P. Bradford,et al.  Phytosterols as anticancer compounds. , 2007, Molecular nutrition & food research.

[23]  C Michael White,et al.  Statins and Cancer Risk: A Meta-analysis , 2007 .

[24]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[25]  J. Kane,et al.  Ezetimibe Effectively Reduces Plasma Plant Sterols in Patients With Sitosterolemia , 2004, Circulation.

[26]  D. Tribble,et al.  Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans , 2002, Circulation.

[27]  P Grasso,et al.  Dose and time relationships for tumor induction in the liver and esophagus of 4080 inbred rats by chronic ingestion of N-nitrosodiethylamine or N-nitrosodimethylamine. , 1991, Cancer research.